Tag: Biofourmis

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

BiovitalsHF® Approved for Expedited FDA Review Process as a First-in-Class DTx for Heart Failure that Augments Traditional Guideline-Directed Medical Therapy BOSTON, July 29, 2021 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device […]

Biofourmis Closes $100 Million Series C Funding Round Led by SoftBank Vision Fund 2 to Accelerate U.S. and Global Expansion

Funding to advance “home hospital” initiatives with health systems and “beyond the pill” digital therapeutics partnerships with pharmaceutical companies BOSTON, Sept. 3, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund […]

Biofourmis names new CFO to help drive the digital therapeutics start-up’s growth plans

Finance leader Matt Borowiecki brings deep M&A and fundraising experience to his new role BOSTON, May 26, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, has named Matt Borowiecki its Chief Financial Officer (CFO) to enhance decision-making related to future strategic investments, and to expand the company’s […]

Biofourmis Partners with ImagineMIC to Pioneer Collaborative Remote Patient Monitoring Model

Biofourmis’ artificial intelligence-powered RhythmAnalytics® to provide clinical decision support that IDs cardiac arrhythmias and other issues requiring intervention BOSTON, Jan. 30, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, and ImagineMIC™ announced a partnership agreement today to drive improved outcomes and lower healthcare costs for […]

Digital therapeutics leader Biofourmis to take part in pioneering heart failure research with Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI)

BOSTON, July 16, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life […]

Biofourmis’ RhythmAnalytics™ Platform Receives FDA Clearance for AI-Based Automated Interpretation of Cardiac Arrhythmias

BOSTON, April 30, 2019 /PRNewswire/ — Biofourmis announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its RhythmAnalyticsTM platform, a cloud-based software for automated interpretation of cardiac arrhythmias. It uses an enhanced deep-learning technique to detect over 15 types of cardiac arrhythmias along with beat-by-beat morphology computation which […]